Dissemination via the lymphatic or angiogenic route impacts the pathology, microenvironment and hypoxia-related drug response of lung metastases

[18F]-FLT Positron Emission Tomography Can Be Used to Image the Response of Sensitive Tumors to PI3-Kinase Inhibition with the Novel Agent GDC-0941

(2013) C. Cawthorne et al.   MOLECULAR CANCER THERAPEUTICS

Tumor location and nature of lymphatic vessels are key determinants of cancer metastasis

(2012) Ramin Shayan et al.   CLINICAL & EXPERIMENTAL METASTASIS

Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation

(2012) Yao Dai et al.   CLINICAL & EXPERIMENTAL METASTASIS

Antimetastatic Effect of Sulfamate Carbonic Anhydrase IX Inhibitors in Breast Carcinoma Xenografts

(2012) Roben G. Gieling et al.   JOURNAL OF MEDICINAL CHEMISTRY

The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy

(2010) S J Lunt et al.   BRITISH JOURNAL OF CANCER

In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts

(2009) K. J. Williams et al.   MOLECULAR CANCER THERAPEUTICS

Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study

(2008) M. R. Albertella et al.   CLINICAL CANCER RESEARCH